Brevan Howard Capital Management LP Takes $261,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Brevan Howard Capital Management LP acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 3,350 shares of the medical device company's stock, valued at approximately $261,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new position in DexCom in the fourth quarter worth approximately $385,367,000. Congress Asset Management Co. boosted its stake in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new position in shares of DexCom in the 4th quarter worth $96,507,000. Northern Trust Corp raised its position in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after purchasing an additional 753,857 shares during the period. Finally, Jennison Associates LLC raised its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

DXCM opened at $84.66 on Monday. The stock has a fifty day moving average price of $71.08 and a 200 day moving average price of $77.22. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26. The stock has a market cap of $33.20 billion, a price-to-earnings ratio of 59.20, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the business earned $0.32 earnings per share. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Canaccord Genuity Group raised their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $98.11.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.